Heart failure & cardiomyopathies

A Bayesian analysis of finerenone in heart failure with mildly reduced and preserved ejection fraction: a pre-specified analysis of FINEARTS-HF

Eur Heart J Cardiovasc PharmacotherPublished pre-specified Bayesian analysis

Primary result · Cardiovascular death and total heart failure eventsResult — go to the resultRelative risk 0.83 95% CrI 0.74–0.94

Authors' conclusion

The non-steroidal MRA finerenone reduced the rate of cardiovascular death and total heart failure events under both frequentist and Bayesian inference methods. The probability of benefit exceeded 80% for both cardiovascular and all-cause mortality with finerenone. Trial Registration: ClinicalTrials.gov Identifier: NCT04435626

Study context

Population
Patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) in the FINEARTS-HF trial
Participants
6,001 patients
Comparison
finerenone vs. placebo
Primary endpoint
cardiovascular death and total heart failure events
Methodological detailsrobust meta-analytic predictive (MAP) prior, vague priors and informative MAP priors
  • Robust meta-analytic predictive (MAP) prior
  • Vague priors and informative MAP priors

Primary result

As reported in the abstract

Cardiovascular death and total heart failure events

Relative risk

0.83

95% CrI 0.74–0.94

Finerenone vs placebo
RR 0.83 (95% CrI 0.74–0.94)
Posterior probability of a ≥ 10% reduction in the primary event rate, incorporating prior evidence
from 90% to 92%

Further findings

OutcomeHR (95% CrI)
Cardiovascular death0.93 (0.79–1.10)
All-cause mortality0.94 (0.83–1.06)
Cardiovascular death — Probability that finerenone reduced cardiovascular death
80%
All-cause mortality — Probability that finerenone reduced all-cause mortality
85%

Original publication

A Bayesian analysis of finerenone in heart failure with mildly reduced and preserved ejection fraction: a pre-specified analysis of FINEARTS-HF. Eur Heart J Cardiovasc Pharmacother. Published 16 February 2026. doi:10.1093/ehjcvp/pvag010

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.